Portfolio Companies News
December 13, 2018Altimmune Announces Clinical Progra...
GAITHERSBURG, Md., Dec. 13, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced updates to its clinical programs and plans to further expand its pipeline. NasoVAX As previously announced in September 2018, a monovalent version o... read more
December 13, 2018Oncopeptides Capital Markets Day De...
Stockholm – December 13, 2018 – Oncopeptides AB (Nasdaq Stockholm: ONCO) will hold its Capital Markets Day in New York tomorrow, Dec 14, between 14:30 – 17:00 CET (8:30-11:00 ET). For those who cannot attend in New York, you can follow this via a webcast. The registration for th... read more
December 13, 2018Orexo regains rights to Zubsolv® i...
Uppsala, Sweden – December 13, 2018 - Orexo AB (publ.), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces that the Company will regain the rights to Zubsolv (buprenorphine and naloxone sublingual tablet) for the treatment of opioid dep... read more
December 12, 2018Targovax Presents at DNB 9th Annual...
Oslo, Norway, 12 December 2018 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, announces that CEO Øystein Soug presented today at DNB 9th Annual Nordic Healthcare Conference in Oslo, Norway. The presentation pr... read more
December 12, 2018National Institute for Health and C...
NICE makes a “strong” recommendation that patients with severe COPD be referred for evaluation for bronchoscopic lung volume reduction, including the Zephyr® Endobronchial Valve System. NICE has broadened the criteria for evaluation and a new group of people for whom lung volume reducti... read more
November 19, 2018Q3 2018 General Market Overview
Since the start in 1996, HealthCap funds have invested in 113 portfolio companies.
42 of the portfolio companies have been taken public on nine different markets.
25 of the portfolio companies’ pharmaceutical products have been approved for marketing.
Since the start in 1996, HealthCap has helped build 7 companies with a valuation of USD 1 billion or more and 35 companies with a valuation of SEK 1 billion or more.